 NEW YORK, Aug. 09, 2021 GLOBE NEWSWIRE -- Delcath Systems, Inc. Nasdaq: DCTH, an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. Avenue Venture Fund providing up to 20 million with an initial 15 million funded at close. Additional details concerning the debt facility will be contained in the companys Current Report on Form 8-K to be filed shortly with the Securities and Exchange Commission. 